SCHEDULE: Bank of America Discloses 5.9% Stake in Inhibrx Biosciences

Bank of America Corporation has reported beneficial ownership of 5.9% of Inhibrx Biosciences, Inc. common stock as of June 30, 2026.

Summary

• Bank of America Corporation, through its subsidiaries, now beneficially owns 857,318 shares of Inhibrx Biosciences, Inc. common stock.
• This represents 5.9% of the class of securities outstanding.
• The filing is made under Schedule 13G, indicating passive investment.
• The reporting date for the event requiring this filing is June 30, 2026.
• The total number of outstanding shares used for this calculation is 14,607,286, as disclosed by the issuer on June 3, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new operational or financial information.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large financial institutions accumulating passive stakes in publicly traded companies, often as part of their asset management or trading operations. This filing indicates Bank of America's investment activity within the biotechnology sector.

Stakeholder Impact

• Shareholders: The filing indicates a significant institutional investor's passive stake, which could be viewed neutrally or positively by the market, suggesting confidence in the company's long-term prospects without active control intentions.

Key Dates

Keywords

beneficial ownership, Schedule 13G, passive investment, common stock, institutional investor